Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jan 17, 2016 6:15pm

103 Views

Post# 24467146

RE:ADD 208 TO A POLY PILL FOR UNTREATED PATIENTS ??? THOUGHTS?

Jkj, that looks to me like very shakey research.

The writing is not very clear. The research design doesn't even seem close to proper double blind trials.

The RRR levels were very insignificant vs. rvx-208 RRR of 77% in patients with CVD, DM and low HDL and the absolute risk reduction levels were minor vs rvx-208 where the absolute risk reduction was 15% points = 21% control - 6% points after 210 days of treatment.

So I don't know what to conclude but I don't think I would use this person's cocktail of drugs.
Cheers
Toinv

Bullboard Posts

Who, why, and what of the great "Crypto Surge"